Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 6, 2017
LIGAND PHARMACEUTICALS INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
|
| | | | |
Delaware | | 001-33093 | | 77-0160744 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
|
| | |
3911 Sorrento Valley Boulevard, Suite 110 San Diego, CA | | 92121 |
(Address of principal executive offices) | | (Zip Code) |
(858) 550-7500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
o
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
o
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
o
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.425) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. o
Item 8.01. Other Events.
On October 6, 2017, pursuant to the terms and conditions of the previously announced Agreement and Plan of Merger, dated October 4, 2017 (the “Merger Agreement”), Ligand Pharmaceuticals Incorporated (“Ligand”) closed its acquisition of Crystal Bioscience, Inc. (“Crystal”). In connection with the closing, Ligand will pay approximately $25 million in initial merger consideration in cash (subject to certain adjustments) and Crystal became a wholly-owned subsidiary of Ligand.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | | |
| | | | | |
| | | LIGAND PHARMACEUTICALS INCORPORATED |
| | | |
Date: October 9, 2017 | | | By: | | /s/ Charles Berkman |
| | | Name: Title: | | Charles Berkman Vice President, General Counsel and Secretary |